エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 7, 2025
iSpecimen Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-40501 | 27-0480143 | ||
| (State or other jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
8 Cabot Road, Suite 1800
Woburn, MA 01801
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (781) 301-6700
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $0.0001 per share | ISPC | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On August 7, 2025, iSpecimen Inc. (the “Company”) issued a press release announcing a major strategic initiative aimed at integrating digital assets into its business model. The Company is looking to build an up to $200 million corporate treasury reserve built around the Solana blockchain ecosystem. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The information in this Item 7.01 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated August 7, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 7, 2025
| iSPECIMEN INC. | |||
| By: | /s/ Robert Bradley Lim | ||
| Name: | Robert Bradley Lim | ||
| Title: | Chief Executive Officer | ||
Exhibit 99.1
iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow
Woburn, MA – August 7, 2025 – iSpecimen Inc. (NASDAQ: ISPC), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced a major strategic initiative aimed at integrating digital assets into its business model. The company is looking to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem.
iSpecimen has retained WestPark Capital to advise on the initiative with any funds that may be allocated or raised to be earmarked for building a digital asset treasury that will support long-term value creation and fuel innovation across iSpecimen’s digital infrastructure.
To ensure the initiative is guided by rigorous strategy and strong compliance, iSpecimen has also contracted with BlockArrow, a leading digital asset advisory and management firm. BlockArrow Capital is a Chicago-based digital asset investment firm founded in 2019, managing two distinct strategies. Fund I is a liquid, actively managed crypto portfolio focused on altcoin outperformance and tactical positioning. Fund II is a Fund of Funds providing diversified exposure to institutional-grade crypto hedge funds and venture strategies, rebalanced at market extremes to optimize risk-adjusted returns. Rooted in long-only, thesis-driven strategies that combine on-chain metrics with fundamental research, founders Thomas Sutker and Dylan Gold draw upon a range of institutional tools—including Coinbase Custody, Ledger, FalconX, Dune Analytics, Token Terminal, and Nansen—to support their data-driven asset management approach.
iSpecimen plans to feature security and investor protection as central components of its treasury structure. BlockArrow employs such a layered security model including offline cold storage, insured custody through Coinbase Custody, and institutional-grade risk controls. Coinbase Custody’s insurance coverage extends to risks such as theft, damage, or operational failures, backed by Lloyd’s of London syndicates.
“This initiative represents a bold step forward in iSpecimen’s pursuit of technological leadership in the life sciences,” said Rob Lim, CEO of iSpecimen. “By building a Solana-based treasury, we believe that we are aligning with the future of decentralized infrastructure and digital assets. Our collaborations with WestPark Capital and BlockArrow are expected to provide the expertise and capital needed to make this vision a reality.”
“At BlockArrow, we specialize in secure, compliant, and forward-thinking crypto strategies,” added Thomas Sutker, Co-Founder of BlockArrow.
The Company plans to diversify its future digital treasury across high-performing crypto assets, with a focus on liquidity, capital preservation, and sustainable growth and plans to initially select Solana as the foundation for its digital asset treasury due to its unique strengths, including:
| ● | High Throughput & Scalability: Solana’s hybrid Proof-of-History and Proof-of-Stake consensus mechanisms allow for fast, low-latency transactions at scale. |
| ● | Low Transaction Costs: Minimal fees make Solana ideal for handling frequent, small transactions—a key requirement for future decentralized applications in research. |
| ● | Developer-Friendly Tools: With an active developer community and frameworks like Anchor, Solana offers a strong base for building custom dApps. |
| ● | Enterprise Security: The Solana Virtual Machine (SVM) provides robust execution for smart contracts with a focus on security and performance. |
“This strategic move reflects iSpecimen’s financial and operational innovation,” said Katie Field, President of iSpecimen. Ms. Field continued, “As blockchain adoption gains momentum, we aim to be a leader—not just an adopter—of digital assets and generating returns via an attractive and well planned portfolio.”
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including the uncertainty regarding future commercial success; risks and uncertainties associated with market conditions, risks related to the regulatory environment for cryptocurrency transactions, and the Company’s ability to develop and maintain its crypto treasury strategy. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Contacts:
info@ispecimen.com